The federal government is fast-tracking some psychedelic-based medicines for research and development. Emergency physician Dr. Jonathan Leak explains how these therapies may work in the brain and if they’re safe.

00:00 — Fire captain recounts suicidal crisis; psilocybin changes his outlook and family life
00:36 — Intro: what psychedelics might do (neurotransmitters/neuroplasticity) and the safety question
00:54 — Why now: executive order to speed development; focus on treatment-resistant depression, PTSD, addiction
01:23 — Arizona psilocybin trial for first responders; content warning for sensitive topics
02:05 — Mark Herman’s story: chronic trauma, “fight or flight,” and seeking relief
03:01 — Research barriers from past criminalization; trial details and demand/waitlist
04:22 — Career risks/stigma for officers; underground use; dosing and safety concerns
05:01 — Black market concerns; funding push; hopes for right-to-try and guardrails as access expands
07:20 — Interview begins: Dr. Leak’s credentials; ketamine currently used in psychedelic therapy
08:15 — What drugs are discussed: psilocybin, ibogaine, methylone/MDMA
09:00 — Evidence/history; why these may help PTSD, depression, addiction
10:53 — How they may work: receptors + neuroplasticity + psychedelic experience; importance of therapy integration
12:36 — Brain connectivity shifts; new pathways; how psilocybin is dosed and how long sessions last
15:01 — Patents/formulations; molecule tweaks vs process patents
16:02 — MDMA/methylone differences; trauma processing and study outcomes; need for certified care
18:08 — Clinic model questions; side effects, monitoring, and scaling sessions safely